Preliminary results from a German study suggest that stroke patients' use of anti-anemia drugs such as Aranesp, Procrit and Epogen might end up boosting their risk for death, the U.S. Food and Drug Administration (FDA) warned on Friday.
The goal of the study was to see if high doses of the anti-anemia drug epoetin alfa could improve the ability of stroke patients to take care of themselves after recovering from a stroke.
The hope was that the drug would be neuroprotective, but use of epoetin alfa now appears linked to a near-doubling of mortality.
More
Showing posts with label Aranesp. Show all posts
Showing posts with label Aranesp. Show all posts
Monday, September 29, 2008
Thursday, February 07, 2008
Amgen - Aranesp: see you in court
A federal judge ruled Friday that Amgen must defend itself against charges it misled investors about safety concerns with its flagship anemia drug, Aranesp.
U.S. District Court Judge Philip S. Gutierrez dismissed charges against five of nine Amgen officers and directors but left plaintiffs 30 days to amend their complaint in order to include those defendants.
The investors, led by Connecticut Retirement Plans and Trust Funds, assert that positive statements made by company officials regarding the safety of Amgen's two anemia drugs, Aranesp and Epogen, were knowingly at odds with clinical studies that had raised concerns.
More
U.S. District Court Judge Philip S. Gutierrez dismissed charges against five of nine Amgen officers and directors but left plaintiffs 30 days to amend their complaint in order to include those defendants.
The investors, led by Connecticut Retirement Plans and Trust Funds, assert that positive statements made by company officials regarding the safety of Amgen's two anemia drugs, Aranesp and Epogen, were knowingly at odds with clinical studies that had raised concerns.
More
Subscribe to:
Posts (Atom)